According to Bavarian Nordic, its cancer vaccine TAEK-VAC has reached a stage where more investments are required. The company would also have faced stiff competition in the cancer vaccine space.
Tag Archive for: Bavarian Nordic
Yesterday the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to recommend that individuals 18 years and older with certain risk factors should receive two doses of Jynneos.
The U.S. Food and Drug Administration has approved GSK Plc’s respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people.
Pfizer Inc and GSK are close to bringing the first two vaccines for RSV to the United States after gaining the backing of a panel of advisers to the FDA.
Danish pharmaceuticals company Bavarian Nordic has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc. for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023.
Both companies’ vaccines produced antibodies 14 days after the first of two shots and were detectable at varying levels in both children and adults for one year, data from the studies conducted in Western Africa showed.
Mpox is expected to no longer be considered a public health emergency in the United States from Feb. 1, 2023, the U.S. health department said on Friday.
Brand Institute, the global leader in pharmaceutical and healthcare-related brand name and identity development, is pleased to share that Denmark-based Bavarian Nordic’s smallpox and monkeypox vaccine, named JYNNEOS®, was selected by TIME Magazine as one of the best inventions of 2022.
The National Institutes of Health said on Thursday it had started enrollments in a trial testing an alternative method of administering Bavarian Nordic’s monkeypox vaccine, Jynneos, which requires smaller dosages.
The European Union said on Wednesday it had secured an additional 170,920 doses of the monkeypox vaccine developed by biotech firm Bavarian Nordic amid concerns about the outbreak of the disease.